IMMEDIATE GRAFT

Perfect for small bony defects

Immediate Graft is a combination of our perio size OsseoConduct beta tricalcium phosphate granules and Socket Graft. It is supplied in small quantities for grafting small bony defects. Immediate Graft is ready to use with no mixing required.

This product is contained in a medical grade silicone tray and should be stored in the freezer until use.

This product contains no human or animal tissue.

Our grafts are categorized by the FDA as both a medical device and a drug. The FDA has allowed SteinerBio to claim that these bone grafts stimulate osteogenesis.

Furthermore, our grafts are expressly cleared by the FDA for implant placement.

All compounds are synthesized ultra-pure, ensuring the process of bone growth is safe, predictable, and effective.

Strengthen Your Practice

Immediate Graft will change your practice when your patients realize our technology is available to them. Your patients now have a choice between a chemically pure, FDA cleared bone graft or the frequently off-putting choice of cadaver tissue. Resorbable synthetics and autografts are the only bone grafts that produce normal bone. Normal bone is the only type of bone that has been shown to support an implant for a lifetime.

Immediate Graft provides the organic and inorganic molecules a bone needs in order to regrow faster, stronger, healthier, and more vital. Our patented SL Factor in our bone graft material targets the osteoblasts within the patient’s bone, initiating the bone regeneration process. Our product has been classified as a drug device and this the drug contained in this product has been shown to stimulate bone formation.

How Does SL Factor Work?

SteinerBio has the only bone grafts on the market that contain a drug that changes the physiology of a bone’s osteoblasts to stimulate osteogenesis. SL Factor, our patented organic compound, enters through the membrane of the osteoblasts and results in the following metabolic activities:

  • SL Factor is absorbed by the osteoblasts
  • SL Factor activates over 300 genes that stimulate the process of bone formation
  • BMP2 and RUNX2 production increases two-fold and reduces osteoclast formation by inhibiting the production of RANK ligand
  • Osteocalcin accumulation is enhanced in the extracellular matrix resulting in excellent mineralization
  • While stored in the osteoblast, SL Factor continues to stimulate bone growth after the synthetic matrix has been resorbed
  • Adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression is inhibited
  • Inflammation is reduced by inhibiting prostaglandin synthesis

“Modern beta tricalcium phosphate bone grafts perform as well or better than allografts or autografts. The negatives of autograft morbidity and cadaver harvesting makes high performing βTCP a superior choice.”

MEMBER:

American Society for Bone and Mineral Research (ASBMR)

Tissue Engineering and Regenerative Medicine International Society (TERMIS)

American Academy of Implant Dentistry (AAID)